|
1
|
Najar MS, Saldanha CL and Banday KA: Approach to urinary tract infections. Indian J Nephrol. 19:129–139. 2009.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ki MR, Park TS, Choi BY and Foxman B: The epidemiology of acute pyelonephritis in South Korea, 1997-1999. Am J Epidemiol. 160:985–993. 2004.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Johnson JR and Russo TA: Acute pyelonephritis in adults. N Engl J Med. 378:48–59. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, et al: International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases society of America and the European society for microbiology and infectious diseases. Clin Infect Dis. 52:e103–e120. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Pietrucha-Dilanchian P and Hooton TM: Diagnosis, treatment, and prevention of urinary tract infection. Microbiol Spectr: doi: 10.1128/microbiolspec.UTI-0021-2015.
|
|
6
|
Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ and Stamm WE: Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious diseases society of America (IDSA) Clin Infect Dis. 29:745–758. 1999.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Bosch-Nicolau P, Falcó V, Viñado B, Andreu A, Len O, Almirante B and Pigrau C: Risk factors that influence the empirical treatment of patients with acute pyelonephritis: A cohort study. Antimicrob Agents Chemother. 61:AAC.01317–17. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Knaus WA, Draper EA, Wagner DP and Zimmerman JE: APACHE II: A severity of disease classification system. Crit Care Med. 13:818–829. 1985.PubMed/NCBI
|
|
9
|
Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW and Lente FV: Chronic Kidney Disease Epidemiology Collaboration: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 145:247–254. 2006.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Clinical and Laboratory Standards Institute (CLSI): Performance standards for antimicrobial susceptibility testing; 17th informational supplement. Approved standard M100-S17. CLSI, Annapolis Junction, MD, 2007.
|
|
11
|
Park SH, Choi SM, Lee DG, Cho SY, Lee HJ, Choi JK, Choi JH and Yoo JH: Impact of extended-spectrum β-lactamase production on treatment outcomes of acute pyelonephritis caused by Escherichia coli in patients without health care-associated risk factors. Antimicrob Agents Chemother. 59:1962–1968. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Tüzün T, Sayın Kutlu S, Kutlu M and Kaleli İ: Risk factors for community-onset urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Turk J Med Sci. 49:1206–1211. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Albaramki JH, Abdelghani T, Dalaeen A, Khdair Ahmad F, Alassaf A, Odeh R and Akl K: Urinary tract infection caused by extended-spectrum β-lactamase-producing bacteria: Risk factors and antibiotic resistance. Pediatr Int. 61:1127–1132. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kim B, Kim J, Seo MR, Wie SH, Cho YK, Lim SK, Lee JS, Kwon KT, Lee H, Cheong HJ, et al: Clinical characteristics of community-acquired acute pyelonephritis caused by ESBL-producing pathogens in South Korea. Infection. 41:603–612. 2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Díaz-Agero Pérez C, López-Fresneña N, Rincon Carlavilla AL, Hernandez Garcia M, Ruiz-Garbajosa P, Aranaz-Andrés JM, Maechler F, Gastmeier P, Bonten MJM and Canton R: Local prevalence of extended-spectrum beta-lactamase (ESBL) producing enterobacteriaceae intestinal carriers at admission and co-expression of ESBL and OXA-48 carbapenemase in Klebsiella pneumoniae: A prevalence survey in a Spanish university hospital. BMJ Open. 9(e024879)2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Karanika S, Karantanos T, Arvanitis M, Grigoras C and Mylonakis E: Fecal colonization with extended-spectrum beta-lactamase-producing enterobacteriaceae and risk factors among healthy individuals: A systemic review and metaanalysis. Clin Infect Dis. 63:310–318. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kim YJ, Lee JM, Cho J and Lee JH: Change in the annual antibiotic susceptibility of Escherichia coli in community-onset urinary tract infection between 2008 and 2017 in a tertiary care hospital in Korea. J Korean Med Sci. 34(e228)2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kang CI, Kim J, Park DW, Kim BN, Ha US, Lee SJ, Yeo JK, Min SK, Lee H and Wie SH: Clinical practice guidelines for the antibiotic treatment of community-acquired urinary tract infections. Infect Chemother. 50:67–100. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Luvsansharav UO, Hirai I, Nakata A, Imura K, Yamauchi K, Niki M, Komalamisra C, Kusolsuk T and Yamamoto Y: Prevalence of and risk factors associated with faecal carriage of CTX-M β-lactamase-producing enterobacteriaceae in rural Thai communities. J Antimicrob Chemother. 67:1769–1774. 2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Schwaber MJ and Carmeli Y: Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in enterobacteriaceae bacteraemia: A systematic review and meta-analysis. J Antimicrob Chemother. 60:913–920. 2007.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Marchaim D, Gottesman T, Schwartz O, Korem M, Maor Y, Rahav G, Karplus R, Lazarovitch T, Braun E, Sprecher H, et al: National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by enterobacteriaceae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 54:5099–5104. 2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Freeman JT, McBride SJ, Nisbet MS, Gamble GD, Williamson DA, Taylor SL and Holland DJ: Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: Risk factors and outcomes. Int J Infect Dis. 16:e371–e374. 2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Qureshi ZA, Paterson DL, Peleg AY, Adams-Haduch JM, Shutt KA, Pakstis DL, Sordillo E, Polsky B, Sandkovsky G, Bhussar MK and Doi Y: Clinical characteristics of bacteraemia caused by extended-spectrum β-lactamase-producing enterobacteriaceae in the era of CTX-M-type and KPC-type β-lactamases. Clin Microbiol Infect. 18:887–893. 2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR and Ko WC: Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: Implications of ertapenem susceptibility. Antimicrob Agents Chemother. 56:2888–2893. 2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Velasco M, Martínez JA, Moreno-Martínez A, Horcajada JP, Ruiz J, Barranco M, Almela M, Vila J and Mensa J: Blood cultures for women with uncomplicated acute pyelonephritis: Are they necessary? Clin Infect Dis. 37:1127–1130. 2003.PubMed/NCBI View Article : Google Scholar
|
